Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry

被引：0
|
作者：
Yun, Huifeng [1 ]
Curtis, Jeffrey [2 ]
Chen, Lang [1 ]
Clinton, Cassie [1 ]
van Hoogstraten, Hubert [3 ]
Fiore, Stefano [3 ]
Rehberg, Markus [4 ]
Choy, Ernest [5 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Dept Epidemiol, Dept Med, Birmingham, AL USA
[3] Sanofi, Bridgewater, NJ USA
[4] Sanofi, Franfurt, Germany
[5] Cardiff Univ, CREATE Ctr, Cardiff, Wales
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1243
引用
收藏
页码：2568 / 2570
页数：3
相关论文
共 50 条
  • [41] An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with Rheumatoid Arthritis
    Edwards, Christopher J.
    Bukowski, Jack F.
    Burns, Sara M.
    Jones, Heather E.
    Pedersen, Ron
    Sopczynski, Joan
    Marshall, Lisa
    DRUGS & AGING, 2020, 37 (01) : 35 - 41
  • [42] THE REAL-WORLD SAFETY OF RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hyrich, Kimme
    RHEUMATOLOGY, 2017, 56 : 24 - 25
  • [43] REAL-WORLD EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Diederik, D. C.
    Durez, P.
    Lenaerts, J.
    Westhovens, R.
    Verschueren, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1398 - 1399
  • [44] An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with Rheumatoid Arthritis
    Christopher J. Edwards
    Jack F. Bukowski
    Sara M. Burns
    Heather E. Jones
    Ron Pedersen
    Joan Sopczynski
    Lisa Marshall
    Drugs & Aging, 2020, 37 : 35 - 41
  • [45] RNASEQ PROFILING OF RHEUMATOID ARTHRITIS PATIENTS TO PREDICT RESPONSE TO TOFACITINIB
    Bellocchi, C.
    Maioli, G.
    Favalli, E. G.
    Agape, E.
    Rossato, M.
    De Quattro, C.
    Severino, A.
    Biggioggero, M.
    Trombetta, E.
    Vigone, B.
    Caporali, R.
    Beretta, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 59 - 60
  • [46] Effectiveness of infliximab in patients with rheumatoid arthritis 'real world' experience
    Barr, SG
    Steber, W
    Kindopp-Bugo, K
    Martin, L
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (08) : 1876 - 1876
  • [47] Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry
    Harrold, Leslie R.
    Griffith, Jenny
    Zueger, Patrick
    Litman, Heather J.
    Gershenson, Bernice
    Islam, Syed S.
    Barr, Christine J.
    Guo, Dianlin
    Fay, Jonathan
    Greenberg, Jeffrey D.
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 959 - 967
  • [48] Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry
    Hiroshi Harada
    Masakazu Kondo
    Akira Maeyama
    Takaaki Fukuda
    Satoshi Ikemura
    Eisuke Shono
    Tomomi Tsuru
    Yasushi Inoue
    Seiji Yoshizawa
    Hiroaki Niiro
    Yasuharu Nakashima
    Clinical Rheumatology, 2024, 43 : 1447 - 1459
  • [49] What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? An Analysis from the Real-world Registry, BioTRAC
    Faraawi, Rafat
    Joshi, Ramen
    Bensen, William
    Choquette, Denis
    Olszynski, Wojciech
    Arendse, Regan
    Sheriff, Maqbool
    Rahman, Proton
    Sampalis, John
    Rampakakis, Emmanouil
    Nantel, Francois
    Lehman, Allen
    Otawa, Susan
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1330 - 1330
  • [50] Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate
    Gabay, Cem
    Msihid, Jerome
    Daskalakis, Nikki
    Graham, Neil
    Barbot, Anne
    Zilberstein, Moshe
    Boyapati, Anita
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345